Triple

Target class: antisense oligonucleotide therapy
Context triple: [Waylivra, instanceOf, antisense oligonucleotide therapy]

• A. antisense oligonucleotide chosen
  An antisense oligonucleotide is a short, synthetic strand of nucleic acid designed to bind specifically to a target RNA sequence and modulate its function, typically to alter gene expression for therapeutic purposes.
• B. Bruton tyrosine kinase inhibitor
  A Bruton tyrosine kinase inhibitor is a targeted small-molecule drug that blocks BTK signaling in B cells to disrupt pathways critical for their activation, proliferation, and survival, primarily used in the treatment of certain B-cell malignancies and autoimmune diseases.
• C. disease-modifying therapy
  A disease-modifying therapy is a treatment that alters the underlying course or mechanisms of a disease to slow its progression, reduce long-term damage, or change its overall outcome rather than just alleviating symptoms.
• D. biologic therapy
  Biologic therapy is a treatment that uses substances made from living organisms or their derivatives to target specific components of the immune system or disease processes.
• E. pegylated interferon beta-1a
  Pegylated interferon beta-1a is a long-acting, pegylated form of interferon used as a disease-modifying therapy to reduce relapses and slow progression in patients with relapsing forms of multiple sclerosis.
• F. None of above.